This paper discusses how changes to
microglia activity could cause depressive-like behaviors. Kreisel
et al. investigated this by measuring the results of chronic stress procedures
on mice and rats. They studied behavioral, pharmacological, molecular, and
biochemical responses to those procedures. They found that after mice underwent
chronic unpredictable stress (CUS) and rats underwent chronic mild stress (CMS),
they displayed more depressive like symptoms such as decreased sucrose
preference and social exploration. They also found a decrease in microglia in
the hippocampus and increased levels of corticosterone. Kreisel et al. found
differences in results when animals were exposed to short-term unpredictable
stress. They found an initial increase in microglia number in the initial stage
of the unpredictable stress procedure, and then a decrease of microglia at the
later stages of the procedure. Kreisel et al. further studied how
anti-depressants could reverse the behavioral and molecular affects of stress. Minocycline
and Imipramine were able to increase microglia number, prevented the suppressive
effects of sucrose preference and social exploration, and increased IL-1
signaling which confirms microglia activation. Lastly, Kreisel et al. studied
the effects of microglia stimulation on depressive-like symptoms, and whether
anti-psychotic drugs were able to reverse these symptoms after CUS exposed mice
established depressive like symptoms, as opposed to during the CUS procedure. Microglia
stimulation by different microglia activators showed mixed results; LPS
improved some depressive like behavior such as in the open field test while
also did not change other types of behavior like sucrose preference and social
exploration. Another activator, M-CSF was able to improve sucrose preference
and social exploration. Anti-psychotic drugs were able to improve some
depressive behaviors and not others.
I found this paper very
interesting because it aims to discover the link between nonneuronal cells like
microglia to psychiatric disorders like depression. There is so little that we
know behind neuropsychopathology of these disorders and I like that Kreisel et
al. sought to study this. I also found it interesting that different types of
depressive behaviors were improve by the antipsychotics while others did not, even
though microglia number and activation increased. Different depressive symptoms
may have different neuropsychopathology than others which may explain the
differences. This goes to show how complex it is to study neuropsychiatric
disorders. Additionally, since microglia takes part in the immune system in the
brain, this paper finds more relationships between immunity and behavioral
functioning. The immune system may play a bigger role than we think when it
comes to psychiatric disorders and may explain how many illnesses are comorbid
with psychiatric disorders. Lastly, Kreisel et al. found differences between
microglia number during different stages of the CUS procedure. The beginning
stages showed increase in number and the later stages did not. Also, the
antipsychotic drugs were able to reverse depressive like symptoms in the
earlier stags as opposed to when the CUS-mice already had established
depressive like symptoms. These findings could provide insight on what
treatment is best for a patient with depression depending on what stage of the
disorder they are in, and based on what symptoms they have.
Some critiques I have were
that Kreisel et al. only used male animals in this study and they had a small
sample size. There data also may not be representative in a clinical setting because
of the use of animals, not humans. There are also sex differences found in
those with major depressive disorder and using female animals in this study
could had addressed these. The paper also did not fully address the biological
mechanisms that take place when microglia is activated during stressful
situations. More studies with diverse and human subjects which aim to find
these mechanisms can provide more insight on finding treatments for different
depressive symptoms, and can hopefully improve psychiatric care.
YES, very disappointing that the work was done only in males
ReplyDelete